Elevated Lipoprotein(a) may increase risk of coronary heart disease among diabetes patients: Study Jacinthlyn Sylvia7 April 2025 8:30 AM ISTA new study published in the recent issue of Atherosclerosis journal showed that lipoprotein(a) [Lp(a)] levels may change the relationship between...
Olpasiran reduced levels of oxidized phospholipids and lipoprotein(a): JAMA Jacinthlyn Sylvia18 March 2025 10:00 AM ISTA new study published in the Journal of American Medical Association showed that the innovative small interfering RNA (siRNA) medication olpasiran...
Lipoprotein(a), ASCVD risk, and Aspirin- What is the Latest Evidence Saying? Dr. Roopali Khanna7 Feb 2025 12:21 PM ISTLipoprotein (a) [Lp(a)] is considered pro-atherosclerotic, pro-inflammatory, pro-thrombotic, and anti-fibrinolytic. Lipoprotein(a) levels >50 mg/dL...
Novel Oral Drug Muvalaplin Lowers Lipoprotein (a) Levels: Clinical Trial Findings Dr. Kamal Kant Kohli20 Nov 2024 9:00 AM ISTA late-breaking clinical trial has shown that muvalaplin, an innovative oral medication, can safely and effectively lower elevated levels of...
Olpasiran effective therapeutic option for lowering lipoprotein(a) levels, suggests study Jacinthlyn Sylvia30 Aug 2024 8:00 AM ISTA new study published in the Journal of the American College of Cardiology found that strong siRNA that lowers lipoprotein(a) (Lp(a)) over an extended...
The Role of Aspirin in Reducing ASCVD Mortality Among Adults with High Lp(a) Concentrations Dr A B Chandorkar8 Aug 2024 11:00 AM ISTAtherosclerotic cardiovascular disease (ASCVD) burden in young individuals is a major health concern, particularly in less developed nations where...
Long-term lipoprotein apheresis promising in reducing CV events in high-risk patients with isolated Lp (a) elevation: Study Medha Baranwal8 Jun 2024 8:45 AM ISTGermany: In a significant breakthrough for high-risk cardiovascular patients with isolated lipoprotein(a) elevation, a pioneering study has unveiled...
Zerlasiran, a promising intervention targeting lipoprotein(a), shows positive results in clinical trial Medha Baranwal3 Jun 2024 9:45 AM ISTUSA: In the realm of cardiovascular health, the quest to combat elevated levels of lipoprotein(a) [Lp(a)], a significant risk factor for...
Elevated Lp(a) independently associated with long-term MACE among individuals with and without baseline ASCVD: JACC Jacinthlyn Sylvia1 March 2024 8:00 PM ISTA recent study unveiled a crucial link between Lipoprotein(a) [Lp(a)] levels and the risk of atherosclerotic cardiovascular disease (ASCVD). The...
Higher serum Lipoprotein A level independent risk factor for mildly reduced eGFR Aditi18 Dec 2023 8:00 AM ISTChronic kidney disease (CKD) is a prevalent global health issue, affecting 10% of the adult population worldwide, with a 29.3% increase in prevalence...
Oral Muvalaplin effectively lowers lipoprotein (a) with no serious adverse effects, shows Initial phase 1 trial Dr. Kamal Kant Kohli6 Sept 2023 11:00 AM ISTAustralia: Daily administration of Muvalaplin, a selective small molecule inhibitor of Lp(a) formation, for 14 days lowered Lipoprotein(a) levels up...
High levels of Lipoprotein(a), raise the risk of recurring coronary heart disease. Isra Zaman14 Jun 2023 9:15 AM ISTIncreased levels of Lipoprotein(a),a variant of 'bad cholesterol', in the bloodstream are a risk factor for recurrent coronary heart disease (CHD) in...
